Introduction
Synthetic cannabinoid drugs have been in widespread use in the USA since approximately 2010. Typically sold as a plant or herbal substrate sprayed with a mixture of chemicals with cannabinoid CB1 agonist activity, the mixtures are smoked for their marijuana-like subjective effects. The actual chemicals used to prepare the smoking mixtures vary and have evolved over the 4 years the products have been in circulation (1, 2) . Recent controls on the sale and possession of the drugs appear to have reduced their prevalence; however, their use is still encountered in suspected impaired driving arrests. We describe a series of driving under the influence of drugs (DUID) cases in which subjects who were suspected of being impaired were evaluated through the Drug Recognition Expert (DRE) protocol or some portion thereof, and subsequently tested positive for one or more synthetic cannabinoid drugs, but tested negative for other commonly abused and therapeutic drugs and alcohol.
Methods
Subjects, samples and behavioral data These cases represent 10 drivers who were evaluated by DRE officers after being arrested for suspicion of DUID. In these 10 cases, the subjects performed or attempted to perform standardized field sobriety tests (SFSTs). An additional two cases are described in which the arresting officer made observations but did not complete the full DRE protocol due to the subjects' incapacitation (hospitalization or injury), which prevented a complete evaluation. The subjects were arrested between February 2010 and November 2011.
The following divided attention tests were performed by the 10 subjects: Romberg balance test, walk-and-turn (WAT) test and the one-leg stand (OLS) test (3, 4) . Subjects were further assessed for the lack of convergence, pupil size and reaction to light, bloodshot eyes and horizontal and vertical gaze nystagmus (HGN and VGN) . Details of the subjects' appearance and behavior, their performance on SFSTs and their physiological indicators including pulse, blood pressure, temperature and muscle tone, were recorded and tabulated from the arrest paperwork.
Whole blood samples were collected from each driver, and toxicology testing for routine therapeutic and abused drugs was performed by gas chromatography mass spectrometry (GC-MS) and enzyme-linked immunosorbent assay (ELISA) for a scope of 300 acidic and basic drugs and their metabolites including central nervous system (CNS) stimulants and depressants, opioids, benzodiazepines, barbiturates and cannabinoids (delta-9-tetrahydrocannabinol, the active constituent of marijuana, and its 11-carboxy metabolite). Subjects were also tested for alcohol use by breath testing proximate to the time of arrest. The timing of the blood sample collection relative to the driving was not consistently recorded in data available to us, so are not reported. Testing for synthetic cannabinoids was carried out based on case history of use or possession, statements made admitting to their use, or as further investigation of cases in which the subject's apparent intoxication was not accounted for by other toxicological findings.
Cases were acquired over a 2-year period during which the scope of synthetic cannabinoid testing in the laboratory changed, becoming more inclusive. Additional compounds were added to the scope of the drug test as they appeared on the illicit drug market, and some compounds initially reported qualitatively due to the lack of deuterated internal standards were later reported quantitatively. Due to limitations on sample volume, early samples were not re-tested as the scope of the test subsequently expanded, and no retrospective attempts at quantitation were made where the initial analysis had been qualitative.
Analysis
The cases had either screened positive for cross-reactive species on a directed synthetic cannabinoid ELISA targeted to JWH-018 and/or JWH-250 metabolites (5) with confirmation using liquid chromatography-tandem mass spectrometry (LC -MS-MS), or were directly screened, confirmed and quantitated by repeat LC-MS-MS analysis. The LC -MS-MS method was based on that described by Kacinko et al. (6) , but to which additional multiple reaction monitoring (MRM) transitions were monitored for newly emerging target analytes. The assay performance characteristics for the new compounds met the standards described in the original publication. During the time in which these cases were acquired, the scope increased ultimately to include the following compounds: AM-2201, AM-694, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-175, JWH-200, JWH-210, JWH-250, RCS-4 and RCS-8.
The limit of quantitation using LC -MS-MS for all synthetic cannabinoids reported quantitatively was determined to be 0.1 ng/mL. In some cases, due to the lack of availability of a suitable deuterated internal standard at the time the test was performed, the presence of the drug was reported qualitatively.
Results
In all the 12 cases described, the subjects were male and the age range was 18 -31 (average 22.4). The results of the synthetic cannabinoid testing are summarized in Table I . All 12 subjects were positive for at least one synthetic cannabinoid, and most were positive for more than one. AM-2201 was encountered in half of the cases, indicating its prevalence in synthetic cannabinoid products during that time window. Concentrations for synthetic cannabinoids ranged from 0.1 to 9.9 ng/mL in blood samples from these drivers. The subjects included in this report tested negative for alcohol and other drugs except in one subject who tested positive for caffeine and nicotine and their metabolites. Psychomotor and behavioral effects observed were, therefore, attributed to the use of synthetic cannabinoids.
Details of the driving behaviors were not available in the cases as only DRE face sheets were submitted; however, in the seven cases in which accident involvement status was indicated, and four of the subjects were involved in motor vehicle collisions.
The DRE's observations with respect to physiological indicators are also summarized in Table I . While there was some variation, the attitude of the drivers was described as cooperative and relaxed, and coordination was generally described as poor. Speech was generally slow and slurred.
Officers noted that the subjects' eyelids were either normal or droopy, and that their eyes were bloodshot or had reddened conjunctiva in 10 of the 11 cases in which this was recorded. The lack of convergence (an inability to cross the eyes) was noted in all eight of the drivers in whom this sign was assessed. HGN was evaluated in nine of the subjects, but was present in only two. VGN was present in only 1 of 10 drivers where it was evaluated. Pupil size ranged from pinpoint to normal to dilated, with no apparent correlation to the presence of synthetic cannabinoids. Pulse rate was generally elevated (90 bpm) in six of nine subjects, with an average value of 97 (range 67 -122) bpm. Systolic blood pressure was elevated (140 mmHg) in six of nine subjects. Diastolic pressure was in the normal range for eight of nine subjects (average 81 mmHg, range 70 -95). In all cases where a DRE evaluated and categorized the impairment (9 cases), cannabis was determined to be the DRE drug category responsible, based on the signs observed.
During the Romberg balance test, subjects were noted to have eyelid and leg tremors and body sway of between 1 and 3 inches. During the WAT test, leg and body tremors were again noted, along with the sway and lack of balance as indicated by raised arms. During the OLS test, sway, leg and body tremors and raised arms for balance were again the most frequently noted clues. One subject (Subject 3) was able to complete the OLS test without any clues or errors, and this subject ultimately tested positive for the highest concentration of synthetic cannabinoids (JWH-018, 9.9 ng/mL and JWH-250, 2.7 ng/mL). There was no evidence of any correlation between the number or degree of errors in SFSTs and the concentration of synthetic cannabinoids measured in the blood, but all subjects had at least some objective indicators of impairment.
The following two cases from the above data are presented in more detail for illustrative purposes. Normal values for the physiological indicators are presented in Table II .
Case 1
This subject was a 19-year-old male who had parked in a corporate office parking lot that he believed to be a hotel. A security officer at the scene requested police assistance as the driver appeared intoxicated and was inappropriately dressed for the weather (no shoes or socks, and no shirt in winter).
A bag of 'K2' was noticed on the floor of the vehicle, and the subject reported that he had smoked 'pretty much the whole bag'. The officer noted he was having a difficult time following the conversation, was very slow in his reaction time and his eyes were glassy with a blank stare. The subject acted inappropriately for his circumstances by giggling throughout the interview process. The subject was asked to perform the WAT and OLS tests. Throughout the completion of these tests, several impairment indicators were present, including body sway, arms raised for balance and not following directions. No clues of nystagmus were observed, and the lack of convergence was not assessed. After the completion of these tests, this subject was arrested for DUID. Time of blood collection relative to arrest was not known. His blood was analyzed and found to contain 1.1 ng/mL of JWH-018.
Case 6
This subject was pulled over for suspected impaired driving and evaluated by a DRE. The officer described the subject's attitude as cooperative and he admitted to a single 'hit' of a 'spice' product shortly before the stop. He was noted to have reddened conjunctivae, normal eyelids, equal pupillary tracking and no VGN or HGN. He did have a lack of convergence. His pupils showed a normal reaction to light and pupillary diameter was normal in room light and darkness. His blood pressure was slightly elevated at 140/90 as was his average pulse of 93 beats per minute. His body temperature was also normal at 98.48. He had a green coating in his oral cavity.
Speech was described as normal. Indicators present during his performance of the OLS, WAT and the Romberg balance tests included raised arms, missing heel-to-toe, muscle tremors and sway. Time of sample collection relative to the time of arrest was not known. His blood was analyzed and found to contain: 1.4 ng/mL, AM-2201; 0.12 ng/mL, JWH-081; 2.5 ng/mL, JWH-122 and 0.10 ng/mL, JWH-210.
Discussion
Since their appearance, synthetic cannabinoid drugs have been recognized as causing physiological changes and impairment in users including effects similar to those of cannabis use. The drugs are recognized as having the potential to be toxic, and their pharmacology and toxicology have been reviewed elsewhere (7, 8) . Table II provides a comparison of the normal values for physiological values assessed by the DRE program together with values of the effects described in the literature for cannabis use, and a summary of the symptoms present in the subjects described here.
Several authors have described the symptomology associated with synthetic cannabinoid use. Auwa¨rter et al. (8) in a 2009 dosing experiment with the synthetic cannabinoids JWH-018 and cannabicyclohexanol (CP47,497) noted red/bloodshot eyes, dry mouth, tachycardia and changes in mood or perception. The period of use was followed by a sense of tiredness and exhaustion lasting 6 -24 h. The subjects self-reported being impaired (8). Sobolevsky et al. (9) reported adverse effects in three subjects using JWH-018 including red/bloodshot eyes, tachycardia, anxiety, hallucinations and paranoia. Teske et al. (10) reported effects in two subjects smoking 'spice' which contained JWH-018 that included burning of the eyes, dry mouth, increased pupil diameter, tachycardia, sickness, sedation and subjective thought disruption with loss of concentration. Subsequent reports of larger cohorts in emergency room populations (11) have described seizures, agitation, hallucinations, inability to move ones arms, combativeness, nausea and vomiting as well as syncope. Lapoint et al. (12) reported a case of an individual presenting with seizures, tachycardia and elevated blood pressure after smoking a product containing JWH-018.
Hermanns-Clausen et al. (13) reported detailed data on adverse event profiles in 29 subjects reporting to an emergency room, who later were confirmed via toxicology testing to have ingested synthetic cannabinoids including CP47,497, JWH-018, JWH-019, JWH-081, JWH-122 and JWH-122. These subjects demonstrated a range of central nervous system effects including restlessness/ agitation (41%), changes in perception/hallucinations (38%), (14) . A survey of synthetic marijuana users reported peak effects of the synthetic drugs being achieved within 5 min, with peak effects ('feeling stoned') lasting only about an hour, less than the high from marijuana (15) . This group of users also reported synthetic cannabinoids as being less sedating than marijuana, but having more unfavorable side effects, including more hangover effects and greater paranoia. Users who reported a preference for synthetic cannabinoids over marijuana cited effect (58%), availability (18.9%) and not as easy to detect in drug screens (14.5%) as reasons (15) . The drivers we reported here shared many of the physiological symptoms, impairment, red/bloodshot eyes, tachycardia and hypertension reported in these other populations, and in addition, we note the consistent presence of the lack of convergence. The time interval between smoking and blood sample collection undoubtedly contributed to the observed discrepancies between observed effects at the time of arrest and concentration at the time of the blood draw, and is being evaluated in ongoing studies. Nystagmus is not typical of marijuana use (3, 4, 16) , and it was absent in seven of nine synthetic cannabinoid users in this series also. Recently, Musshoff et al. (17) described a series of seven subjects some of whom exhibited impairment in their driving following toxicologically confirmed synthetic cannabinoid use. As in our cases, the drugs involved included JWH-018, AM-2201, JWH-210, JWH-122 and some others. The concentrations reported were similar to those in the subjects we report here also (Table III) , with concentrations between 0.10 and 7.6 ng/mL. Those subjects also exhibited effects similar to the effects described in our subjects, including slurred speech, dilated pupils, confusion, instability and slowed movement. The authors concluded that synthetic cannabinoids can lead to impairment similar to typical performance deficits caused by cannabis use, which are not compatible with safe driving (17) .
Musshoff et al. did not evaluate performance in field sobriety tests; however, in our subjects there were consistent errors in divided attention, sway, muscle tremors and balance in many subjects attributed to their synthetic cannabinoid use. In our series, one subject (Subject 3) with the highest measured concentration of any synthetic cannabinoid successfully completed the OLS test without errors. Other studies have suggested that the field sobriety test battery used in the USA may be insensitive to the effects of marijuana in otherwise impaired drivers (16, 18, 19) , only showing indicators when other cognitive effects are most pronounced.
The general effect profile for synthetic cannabinoids described in published adverse event reports discussed above, include anxiety, paranoia, sedation, agitation, hallucinations and feelings of 'being stoned', all of which clearly indicate the impairing potential of the synthetic cannabinoid drug class. The cognitive and psychomotor effects in the series of drivers reported here most likely contributed to the driving behaviors that brought them to the attention of the police. Physiological indicators including increased pulse and blood pressure were also consistent with the clinical adverse event reports discussed above. The DRE officers appropriately classified these drivers in the cannabis category in the DRE matrix based on their observations of increased pulse and blood pressure, lack of convergence, lack of nystagmus and problems with balance and body position, sway and muscle tremors. Further structured study of the effects of synthetic cannabinoids in naı¨ve and experienced users is needed for a more complete understanding of the circumstances of dosing, effects of tolerance and interaction with other drugs including alcohol, which may make impairment more or less likely.
